Bestrophin 1
(Redirected from VMD2)
Bestrophin 1 (Best1) is a protein that in humans is encoded by the BEST1 gene. This protein is a member of the bestrophin family of anion channels and is primarily expressed in the retinal pigment epithelium (RPE) of the eye. Bestrophin 1 plays a crucial role in the regulation of ion transport and cellular volume in the RPE.
Function[edit | edit source]
Bestrophin 1 functions as a calcium-activated chloride channel. It is involved in the transport of chloride ions across the cell membrane, which is essential for maintaining the ionic balance and proper functioning of the retinal pigment epithelium. The activity of Bestrophin 1 is regulated by intracellular calcium levels, and it contributes to the generation of the light peak in the electrooculogram (EOG).
Clinical Significance[edit | edit source]
Mutations in the BEST1 gene are associated with several retinal dystrophies, including Best vitelliform macular dystrophy (BVMD), also known as Best disease, adult-onset vitelliform macular dystrophy (AVMD), and autosomal recessive bestrophinopathy (ARB). These conditions are characterized by the accumulation of lipofuscin in the RPE, leading to progressive vision loss.
Best Vitelliform Macular Dystrophy[edit | edit source]
Best vitelliform macular dystrophy is an autosomal dominant disorder that typically presents in childhood or adolescence. It is characterized by the presence of a yellowish lesion in the macula, which resembles an egg yolk. Over time, this lesion can break down, leading to atrophy of the RPE and photoreceptor cells, resulting in central vision loss.
Adult-Onset Vitelliform Macular Dystrophy[edit | edit source]
Adult-onset vitelliform macular dystrophy presents later in life, usually in the fourth or fifth decade. The clinical features are similar to those of Best disease, but the progression is generally slower, and the visual prognosis is better.
Autosomal Recessive Bestrophinopathy[edit | edit source]
Autosomal recessive bestrophinopathy is a rare condition caused by biallelic mutations in the BEST1 gene. It is characterized by widespread RPE abnormalities, leading to severe visual impairment. Patients may also exhibit angle-closure glaucoma and a shallow anterior chamber.
Structure[edit | edit source]
Bestrophin 1 is a transmembrane protein with four to six transmembrane domains. The exact topology of the protein is still under investigation, but it is known to form homo-oligomeric complexes that function as chloride channels. The protein's structure is crucial for its function, and mutations that disrupt its conformation can lead to disease.
Research[edit | edit source]
Ongoing research is focused on understanding the precise mechanisms by which Bestrophin 1 regulates ion transport and how mutations in the BEST1 gene lead to retinal dystrophies. Studies are also exploring potential therapeutic approaches, including gene therapy, to treat conditions associated with BEST1 mutations.
Related Pages[edit | edit source]
- Best vitelliform macular dystrophy
- Adult-onset vitelliform macular dystrophy
- Autosomal recessive bestrophinopathy
- Retinal pigment epithelium
- Electrooculogram
- Chloride channel
References[edit | edit source]
External Links[edit | edit source]
Transform your life with W8MD's budget GLP1 injections from $125
W8MD offers a medical weight loss program NYC and a clinic to lose weight in Philadelphia. Our W8MD's physician supervised medical weight loss centers in NYC provides expert medical guidance, and offers telemedicine options for convenience.
Why choose W8MD?
- Comprehensive care with FDA-approved weight loss medications including:
- loss injections in NYC both generic and brand names:
- weight loss medications including Phentermine, Qsymia, Diethylpropion etc.
- Accept most insurances for visits or discounted self pay cost.
- Generic weight loss injections starting from just $125.00 for the starting dose
- In person weight loss NYC and telemedicine medical weight loss options in New York city available
- Budget GLP1 weight loss injections in NYC starting from $125.00 biweekly with insurance!
Book Your Appointment
Start your NYC weight loss journey today at our NYC medical weight loss, and Philadelphia medical weight loss Call (718)946-5500 for NY and 215 676 2334 for PA
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's NYC physician weight loss.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available. Call 718 946 5500.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD